Company news
IGC Pharma, Inc. news in 2026
IGC Pharma, Inc.'s news releases, calls and decks from 2026, newest first.
IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment
October 13, 2026
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026
September 28, 2026
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure
August 17, 2026
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
August 11, 2026
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
July 29, 2026
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
July 7, 2026
IGC Pharma (NYSE: IGC) CEO and CFO Acquire More Than 4.2 Million Shares
July 2, 2026
IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment
May 19, 2026
IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference
May 15, 2026
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
April 22, 2026
IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia
April 20, 2026
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
April 14, 2026
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
April 8, 2026
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease
April 7, 2026
IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
March 30, 2026
New to The Street and IGC Pharma (NYSE American: IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning
March 25, 2026
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
March 19, 2026
IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026
March 18, 2026
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research
February 26, 2026
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets
February 24, 2026
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
February 23, 2026
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances
February 17, 2026
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets
February 12, 2026
IGC Pharma Announces Equity Research Update by Alliance Global Partners
February 10, 2026
IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center
February 9, 2026
IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation
February 2, 2026
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York
January 22, 2026
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia
January 12, 2026
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability
January 6, 2026
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial
January 5, 2026
Decks in 2026
- Investor Presentation (July 2026)
Investor deck · 25 slides · Jul 14, 2026